iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Trading Down 0% – Here’s Why

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) dropped 0% during trading on Tuesday . The company traded as low as $83.47 and last traded at $84.14. Approximately 22,915 shares changed hands during trading, a decline of 76% from the average daily volume of 95,904 shares. The stock had previously closed at $84.17.

iShares U.S. Pharmaceuticals ETF Price Performance

The company’s 50-day moving average is $88.14 and its 200-day moving average is $82.12. The firm has a market capitalization of $955.02 million, a price-to-earnings ratio of 17.75 and a beta of 0.54.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

Several institutional investors have recently made changes to their positions in the stock. Mather Group LLC. purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter worth $38,000. EFG International AG purchased a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at about $38,000. Assetmark Inc. grew its position in iShares U.S. Pharmaceuticals ETF by 203.9% during the fourth quarter. Assetmark Inc. now owns 465 shares of the company’s stock valued at $39,000 after acquiring an additional 312 shares during the period. O Shaughnessy Asset Management LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 35.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock worth $39,000 after acquiring an additional 120 shares during the last quarter. Finally, Blueline Advisors LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF during the fourth quarter worth about $41,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.